S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
Log in

ACADIA Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:ACAD)

$47.08
-0.45 (-0.95 %)
(As of 11/22/2019 04:00 PM ET)
Today's Range
$46.84
Now: $47.08
$48.21
50-Day Range
$37.67
MA: $42.15
$47.68
52-Week Range
$14.01
Now: $47.08
$48.21
Volume646,100 shs
Average Volume1.57 million shs
Market Capitalization$7.25 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.82
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACAD
CUSIPN/A
Phone858-558-2871

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$223.81 million
Book Value$4.48 per share

Profitability

Net Income$-245,190,000.00

Miscellaneous

Employees465
Market Cap$7.25 billion
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive ACAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.


ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its earnings results on Wednesday, October, 30th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.11. The biopharmaceutical company earned $94.59 million during the quarter, compared to analyst estimates of $88.49 million. ACADIA Pharmaceuticals had a negative net margin of 82.48% and a negative return on equity of 50.15%. The firm's quarterly revenue was up 62.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.50) earnings per share. View ACADIA Pharmaceuticals' Earnings History.

When is ACADIA Pharmaceuticals' next earnings date?

ACADIA Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for ACADIA Pharmaceuticals.

What price target have analysts set for ACAD?

14 analysts have issued 12 month target prices for ACADIA Pharmaceuticals' shares. Their forecasts range from $31.00 to $66.00. On average, they anticipate ACADIA Pharmaceuticals' stock price to reach $50.00 in the next year. This suggests a possible upside of 6.2% from the stock's current price. View Analyst Price Targets for ACADIA Pharmaceuticals.

What is the consensus analysts' recommendation for ACADIA Pharmaceuticals?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 3 hold ratings, 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ACADIA Pharmaceuticals.

What are Wall Street analysts saying about ACADIA Pharmaceuticals stock?

Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (11/6/2019)
  • 2. HC Wainwright analysts commented, "Our $60 PT is based on an equally weighted composite of: (a) $71.86/share, as a 35x multiple of taxed and diluted FY22 GAAP EPS of $3.50 discounted back to and (b) an NPV of $47.36/share (discount rate 10%, growth rate 2%). Risks to our investment thesis and target price include: (1) failure of Nuplazid in further clinical studies; (2) failure of Nuplazid to secure regulatory approval in further indications; and (3) failure of Nuplazid to achieve peak commercial revenue estimates in our model, due to market size, penetration rates, and pricing." (5/3/2019)
  • 3. JPMorgan Chase & Co. analysts commented, "Dexcom posted another sizable sales beat, besting consensus expectation by almost $35M, and raised 2019 revenue guidance by $75M. The familiar topics of pricing and competition ruled much of the discussion, but there was little new on either front, in our view. Some revenue is expected to go toward higher operating expenses as the company invests in new markets, the Verily product, and G6 line extensions. We remain concerned that pricing pressures could arise—perhaps suddenly—but also may not occur for years. We frankly haven’t figured out what work to do to predict when or if insurers may push on price due to competition pricing lower. We remain Neutral as we feel we have no way to eliminate or estimate this risk but do believe DXCM shares will move higher should pricing fears not play out. CGM is good medicine and should be used by all MDI diabetics, in our view." (5/2/2019)
  • 4. Cantor Fitzgerald analysts commented, "We are OW on ACAD with a 12-month PT of $30 based on NUPLAZID/pimavanserin in PDP/other neuropsych indications. NUPLAZID remains the only agent approved for PDP against a class of atypical antipsych drugs used off-label. In our view, new patient/revs growth should resume as an awareness campaign gains traction. We see increasingly visible broadening clinical evaluation of pima’ in DRP (and other psych indications) as fueling LT growth, and believe the PoS for these studies is underappreciated at current trading levels. Valuation Summary In valuing ACAD, we used a discounted NPV revenue calculation." (4/25/2019)

Has ACADIA Pharmaceuticals been receiving favorable news coverage?

News stories about ACAD stock have trended negative on Friday, according to InfoTrie. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ACADIA Pharmaceuticals earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for ACADIA Pharmaceuticals.

Who are some of ACADIA Pharmaceuticals' key competitors?

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), Celgene (CELG), Sarepta Therapeutics (SRPT), Synergy Pharmaceuticals (SGYP), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Omeros (OMER), Citigroup (C) and Gilead Sciences (GILD).

Who are ACADIA Pharmaceuticals' key executives?

ACADIA Pharmaceuticals' management team includes the folowing people:
  • Mr. Stephen R. Davis, CEO & Director (Age 58)
  • Dr. Srdjan R. Stankovic, Pres (Age 62)
  • Mr. Michael J. Yang, Exec. VP & Chief Commercial Officer (Age 57)
  • Ms. Elena H. Ridloff C.F.A., CFA, Exec. VP & CFO (Age 39)
  • Mr. Eric Alejandro Miller, Controller & Principal Accounting Officer (Age 40)

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include First Trust Advisors LP (1.75%), Eagle Asset Management Inc. (0.70%), Peregrine Capital Management LLC (0.27%), California Public Employees Retirement System (0.15%), Alps Advisors Inc. (0.15%) and Wealthstreet Investment Advisors LLC (0.10%). Company insiders that own ACADIA Pharmaceuticals stock include Bros Advisors Lp Baker, Daniel B Soland, Eric Alejandro Miller, Glenn Baity, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic and Stephen Davis. View Institutional Ownership Trends for ACADIA Pharmaceuticals.

Which institutional investors are selling ACADIA Pharmaceuticals stock?

ACAD stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Peregrine Capital Management LLC, Alps Advisors Inc., Tocqueville Asset Management L.P., Garrison Bradford & Associates Inc., First Midwest Bank Trust Division, Russell Investments Group Ltd. and Mackay Shields LLC. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Eric Alejandro Miller, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic and Stephen Davis. View Insider Buying and Selling for ACADIA Pharmaceuticals.

Which institutional investors are buying ACADIA Pharmaceuticals stock?

ACAD stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, State of New Jersey Common Pension Fund D, Lisanti Capital Growth LLC, Chartwell Investment Partners LLC, Assenagon Asset Management S.A., Chicago Equity Partners LLC, Campbell & CO Investment Adviser LLC and SG Americas Securities LLC. Company insiders that have bought ACADIA Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker and Daniel B Soland. View Insider Buying and Selling for ACADIA Pharmaceuticals.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $47.08.

How big of a company is ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals has a market capitalization of $7.25 billion and generates $223.81 million in revenue each year. The biopharmaceutical company earns $-245,190,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. ACADIA Pharmaceuticals employs 465 workers across the globe.View Additional Information About ACADIA Pharmaceuticals.

What is ACADIA Pharmaceuticals' official website?

The official website for ACADIA Pharmaceuticals is http://www.acadia-pharm.com/.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]


MarketBeat Community Rating for ACADIA Pharmaceuticals (NASDAQ ACAD)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  703 (Vote Outperform)
Underperform Votes:  380 (Vote Underperform)
Total Votes:  1,083
MarketBeat's community ratings are surveys of what our community members think about ACADIA Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/22/2019 by MarketBeat.com Staff

Featured Article: What Are Treasury Bonds?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel